Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring
Author:
Affiliation:
1. Department of Pharmacy, Shiga University of Medical Science Hospital
2. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
Publisher
Pharmaceutical Society of Japan
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Link
https://www.jstage.jst.go.jp/article/bpb/45/7/45_b21-01098/_pdf
Reference102 articles.
1. 1) Lyashchenko AK, Cremers S. On precision dosing of oral small molecule drugs in oncology. Br. J. Clin. Pharmacol., 87, 263–270 (2021).
2. 2) Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol. Ther., 152, 125–134 (2015).
3. 3) Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol., 30, 4017–4025 (2012).
4. 4) Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin. Pharmacokinet., 53, 305–325 (2014).
5. 5) de Wit D, Guchelaar HJ, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? Drug Discov. Today, 20, 18–36 (2015).
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08
2. Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice;Pharmacology Research & Perspectives;2024-07-11
3. Management of high-alert medications by clinical pharmacological approaches;Folia Pharmacologica Japonica;2024-03-01
4. Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review;Therapeutic Advances in Medical Oncology;2024-01
5. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer;Thyroid®;2023-11-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3